Lilly enlists a long-incubating RNA upstart in new $1.25B partnership

For nearly a decade after Imperial College London professor Nagy Habib launched MiNA Therapeutics around a new kind of RNA in 2008, the company made virtually no announcement: no venture capital raised, no collaborations signed. Now, it’s like a fire hose.